Zimmer Biomet Holdings, Inc. ZBH
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position can be maintained pending the Q2 report for clearer direction.
Stable profitability, strong cash flows and raised guidance after the Q2 report support the continued HOLD signal.
The market reacts positively to the earnings beat and raised guidance, with strengthened analyst consensus toward buy.
HOLD is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 6 Sep 2026 — Report shows organic growth and earnings beat that support raised full-year guidance.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Zimmer Biomet is a leading medical technology company that develops and sells orthopedic implants for knees, hips and extremities as well as robot-assisted surgical solutions such as the ROSA platform. The company holds a strong market position in orthopedics with recurring revenues from implants and surgical tools.
Bull case
Raised full-year guidance and strong growth in technology and robotics segments support the stock.
Bear case
High leverage and weaker performance in certain international markets limit upside.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| ROSA robotics adoption | Slower installations → lower growth in the surgical segment and weaker organic development. | Faster adoption → higher robotics revenues and improved competitive position versus Stryker and J&J. |
| Monogram robotic platform | Regulatory approval delays → postponed commercialization and reduced growth contribution. | Early clearances → accelerated market penetration and improved product mix. |
Why this signal
Stable profitability, strong cash flows and raised guidance after the Q2 report support the continued HOLD signal.
Recent news
Q2 2026 results showed revenue of USD 2.177 billion with 4.0 % organic growth. The company beat adjusted EPS estimates at USD 2.07 and raised full-year guidance. The board approved a quarterly dividend of USD 0.24 per share with record date 30 September. Mixed Reality navigation for shoulder arthroplasty is under clinical evaluation and a partnership with Grace College has been announced. The CEO reports that the sales force restructuring is progressing better than expected.